1. How to submit my research paper? What’s the process of publication of my paper?
The journal receives submitted manuscripts via email only. Please submit your research paper in .doc or.pdf format to the submission email: ijlbpr@ejournal.net.
You’ll be given a paper number if your submission is successful. Your paper then will undergo peer review process, which may take approximately one and a half months under normal circumstances, three tops.
After blind peer review, you will receive the notification letter with the review result of your paper...
2. Can I submit an abstract?
The journal publishes full research papers. So only full paper submission should be [Read More]

Efficacy of Nanoparticle Engineered Drugs in the Treatment of Colorectal Cancer after Failure of Standard Chemotherapy

Sourabh Tiwari
Department of Biotechnology, Govt. PG College, Pipariya
Abstract—Chemotherapy represents a powerful therapeutic keystone in the development of present day cancer therapy. It is one of the most efficient and potent approach to treat colorectal cancer. On the other hand, the failure of chemotherapeutic drugs to selectively target cancer cells remains an important obstacle to successful chemotherapy. More or less all the anticancer drugs have severe side effects on normal tissues and organs. The undesired toxicity of currently available anticancer drugs and the inefficiency of chemotherapeutic treatments have limited the optimization of drug regimens and effective chemotherapeutic procedures. At present the field of nanomedicine allows the release of anticancer drugs by biodegradation and self-regulation of nano materials in vitro and in vivo. For that reason, a need is felt to entrap these drugs into enhanced drug delivery carriers such as SLN to minimize systemic side effects. In the current study SLN was prepared by solvent injection method and built-in with 5-fluorouracil, irinotecan and Ca-leucovorin. In this study we evaluated the apoptotic potential of the nano-engineered formulations was investigated using cultured HT-29 cells. Evaluation of anti-carcinogenic potential by Annexin-V-FITC/PI apoptosis assay and caspase-3 following dose dependent experiments treatment with SLN and native drugs described significant differences, creating better prospective efficacy of nano-engineered drugs. The result indicates that the SLN is a promising controlled release carrier. Nanoparticles as drug delivery systems allow exclusive approaches for cancer treatment. 

Index Terms—colorectal cancer, chemotherapy, toxicity, nanoparticles, cytotoxicity, apoptosis

Cite: Sourabh Tiwari, "Efficacy of Nanoparticle Engineered Drugs in the Treatment of Colorectal Cancer after Failure of Standard Chemotherapy," International Journal of Life Sciences Biotechnology and Pharma Research, Vol. 3, No. 4, pp. 103-108, October 2014.
Copyright © 2012-2015 International Journal of Life Sciences Biotechnology and Pharma Research, All Rights Reserved